A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL

Enrollment

248

Participants

Timeline

Start Date

October 5, 2017

Primary Completion Date

January 8, 2019

Study Completion Date

January 8, 2019

Conditions

Rheumatoid Arthritis, DMARD-naive and Early Disease Patients

Interventions

DRUG

CR6086

oral CR6086 capsules

DRUG

Methotrexate

oral Methotrexate tablets

DRUG

Placebo

oral CR6086 Placebo capsules

Trial Locations (1)

Institute of Rheumatology, Prague